RATIONALE: In order to improve upon the pharmacological properties of the neuroactive steroid ganaxolone, it was used as the starting point in the design of novel neurosteroids that replace the 17β-acetyl side chain with an isoxazole bioisostere. OBJECTIVES: UCI-50027 (3-[3α-hydroxy-3β-methyl-5α-androstan-17β-yl]-5-(hydroxymethyl)isoxazole) was designed as an orally active neuroactive steroid specifically targeted at the gamma-aminobutyric acid(A) receptor (GABAAR). METHODS: UCI-50027 was tested in vitro in Xenopus oocytes expressing human GABAARs and in vivo as an anticonvulsant, for ataxic effects and for anxiolytic activity. RESULTS: In vitro, UCI-50027 dose-dependently enhanced the activity of GABA at human α1β2γ2L, α2β1γ2L, and α4β3δ GABAARs. Consistent with its action as a positive allosteric modulator (PAM), it had no direct activity in the absence of GABA. UCI-50027 protected against acute pentylenetetrazol (PTZ)-induced convulsions with an ED50 of 6 mg/kg p.o. In the rotarod (RR) paradigm in mice, the AD50 (the ataxic dose where half of the animals fail the RR test) was found to be 38 mg/kg p.o., giving a therapeutic index (TI = RR AD50/PTZ ED50)∼6 versus 2.8 for ganaxolone. In the mouse-elevated plus maze (EPM) model for anxiety, UCI-50027 showed a minimum effective dose (MED) ≤0.3 mg/kg p.o. Thus, the TI (TI = RR AD50/EPM MED) for the compound as an anxiolytic is ≥127 versus 3.3 for ganaxolone. CONCLUSIONS: UCI-50027 is an orally active neuroactive steroid with pharmacological activity consistent with a GABAAR PAM that has an improved separation between anticonvulsant/anxiolytic and rotarod effects, potent activity as an anticonvulsant and anxiolytic when compared to ganaxolone.
RATIONALE: In order to improve upon the pharmacological properties of the neuroactive steroidganaxolone, it was used as the starting point in the design of novel neurosteroids that replace the 17β-acetyl side chain with an isoxazole bioisostere. OBJECTIVES: UCI-50027 (3-[3α-hydroxy-3β-methyl-5α-androstan-17β-yl]-5-(hydroxymethyl)isoxazole) was designed as an orally active neuroactive steroid specifically targeted at the gamma-aminobutyric acid(A) receptor (GABAAR). METHODS: UCI-50027 was tested in vitro in Xenopus oocytes expressing human GABAARs and in vivo as an anticonvulsant, for ataxic effects and for anxiolytic activity. RESULTS: In vitro, UCI-50027 dose-dependently enhanced the activity of GABA at human α1β2γ2L, α2β1γ2L, and α4β3δ GABAARs. Consistent with its action as a positive allosteric modulator (PAM), it had no direct activity in the absence of GABA. UCI-50027 protected against acute pentylenetetrazol (PTZ)-induced convulsions with an ED50 of 6 mg/kg p.o. In the rotarod (RR) paradigm in mice, the AD50 (the ataxic dose where half of the animals fail the RR test) was found to be 38 mg/kg p.o., giving a therapeutic index (TI = RR AD50/PTZ ED50)∼6 versus 2.8 for ganaxolone. In the mouse-elevated plus maze (EPM) model for anxiety, UCI-50027 showed a minimum effective dose (MED) ≤0.3 mg/kg p.o. Thus, the TI (TI = RR AD50/EPM MED) for the compound as an anxiolytic is ≥127 versus 3.3 for ganaxolone. CONCLUSIONS: UCI-50027 is an orally active neuroactive steroid with pharmacological activity consistent with a GABAAR PAM that has an improved separation between anticonvulsant/anxiolytic and rotarod effects, potent activity as an anticonvulsant and anxiolytic when compared to ganaxolone.
Authors: Herman J Ng; Edward R Whittemore; Minhtam B Tran; Derk J Hogenkamp; Ron S Broide; Timothy B Johnstone; Lijun Zheng; Karen E Stevens; Kelvin W Gee Journal: Proc Natl Acad Sci U S A Date: 2007-04-30 Impact factor: 11.205
Authors: D J Hogenkamp; S H Tahir; J E Hawkinson; R B Upasani; M Alauddin; C L Kimbrough; M Acosta-Burruel; E R Whittemore; R M Woodward; N C Lan; K W Gee; M B Bolger Journal: J Med Chem Date: 1997-01-03 Impact factor: 7.446
Authors: R B Carter; P L Wood; S Wieland; J E Hawkinson; D Belelli; J J Lambert; H S White; H H Wolf; S Mirsadeghi; S H Tahir; M B Bolger; N C Lan; K W Gee Journal: J Pharmacol Exp Ther Date: 1997-03 Impact factor: 4.030
Authors: Derk J Hogenkamp; Timothy B C Johnstone; Jin-Cheng Huang; Wen-Yen Li; Minhtam Tran; Edward R Whittemore; Rudy E Bagnera; Kelvin W Gee Journal: J Med Chem Date: 2007-06-16 Impact factor: 7.446
Authors: Kelvin W Gee; Minhtam B Tran; Derk J Hogenkamp; Timothy B Johnstone; Rudy E Bagnera; Ryan F Yoshimura; Jin-Cheng Huang; James D Belluzzi; Edward R Whittemore Journal: J Pharmacol Exp Ther Date: 2009-11-25 Impact factor: 4.030
Authors: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White Journal: Epilepsy Res Date: 2012-12-04 Impact factor: 3.045
Authors: Ryan F Yoshimura; Minhtam B Tran; Derk J Hogenkamp; Timothy B Johnstone; Jennifer Y Xie; Frank Porreca; Kelvin W Gee Journal: J Psychopharmacol Date: 2013-10-09 Impact factor: 4.153
Authors: Barak W Gunter; Sherman A Jones; Ian A Paul; Donna M Platt; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2016-06-29 Impact factor: 4.530
Authors: Selwyn S Jayakar; David C Chiara; Xiaojuan Zhou; Bo Wu; Karol S Bruzik; Keith W Miller; Jonathan B Cohen Journal: J Biol Chem Date: 2020-06-15 Impact factor: 5.157